Jennifer Taubert

Jennifer Taubert has been with Johnson & Johnson—which reported 2024 enterprise sales of $88.2 billion and operational sales growth of 5.9%—since 2005, serving in roles including president of internal medicine, and company group chairman of  the Americas. She is now the leader of the innovative medicine business, delivering new medicines to prevent and treat cancer, immune-related disorders, mental illness, cardiovascular disease, and pulmonary hypertension. Under her leadership, J&J Innovative Medicine has become the second-largest pharmaceuticals business globally, with approximately $57 billion in worldwide revenue. In Q1, the division delivered a 4.2% operational sales growth despite having lost exclusivity for its billion-dollar plaque psoriasis product Stelara. J&J’s cancer treatment Carvykti saw over 100% growth in the first quarter. And Tremfya, recently approved for Crohn’s disease, saw first quarter sales of nearly $1 billion and over 20% operational growth, making it the fastest-growing product in the ulcerative colitis market.